Positive results in ONSET-2 phase 3 trial of varenicline nasal spray for treatment of dry eye disease

Study (n=758) found improvement in Schirmer’s score from baseline to week 4; in a greater proportion of patients in the varenicline 0.6 mg/ml (44%) and 1.2 mg/ml (47%) twice daily groups vs control (vehicle) spray twice daily (26%; p<0.0001).

SPS commentary:

Varenicline is a highly selective nicotinic acetylcholine receptor agonist. The parasympathetic nervous system, controls tear film homeostasis partially via the trigeminal nerve which is accessible within the nose. Currently in the UK, varenicline is available only in tablet form for smoking cessation in adults.

Biospace Inc.